Contraception Clinical Trial
Official title:
Can Integration of Family Planning Services Into Anticoagulation Monitoring Services Improve Uptake of Long-Acting Reversible Contraception?
Currently there are approximately 400 women of reproductive age enrolled in outpatient monitoring of warfarin therapy through AMS. The investigators do not have any data on the percentage of women who are using family planning, but anecdotally the providers report that it is very low. The investigators believe that an educational intervention with an emphasis on the safest and most effective methods, long-acting reversible contraception (LARC), aimed specifically toward women with medical conditions requiring anticoagulation, combined with on-site provision of LARC can improve uptake of these methods. Ultimately, the use of the most effective methods of contraception will prevent unplanned pregnancy and the unnecessary maternal morbidity and mortality associated with high-risk pregnancies in women with these conditions.
The investigators' hypothesis is that implementation of an educational intervention
emphasizing long-acting reversible contraception (LARC) combined with free on-site provision
of LARC within Anticoagulation Monitoring Service (AMS) can improve uptake of these methods
by 250% in this population.
Our objectives are to:
1. Determine whether integration of education about and free provision of highly effective
long-acting reversible contraceptive methods within Anticoagulation Monitoring Services
(AMS) is feasible.
2. Determine whether integration of education about and free provision of highly effective
long-acting reversible contraceptive methods within Anticoagulation Monitoring Services
(AMS) can improve uptake of long-acting reversible contraceptive methods (IUCDs and
contraceptive implants).
3. Determine whether integration of education about and free provision of highly effective
long-acting reversible contraceptive methods within an Anticoagulation Monitoring
Services (AMS) Clinic can prevent unplanned pregnancies.
The investigators will perform a prospective cohort study of all women of reproductive age
seen in Anticoagulation Monitoring Service (AMS). Women who agree to enrollment will undergo
our intervention, which will include an educational intervention and free on-site provision
of all reversible contraceptive options, including LARC. This educational intervention will
be a one-on-one educational session on all available methods of contraception, with an
emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the
importance of planning a pregnancy in women with medical conditions requiring
anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning
counseling and provision will provide all counseling and discussions in Kiswahili. Women will
then be offered free, on-site provision of whichever contraceptive method they choose by a
trained provider. During the intervention period we intend to capture all women currently
actively enrolled in AMS, which is currently approximately 400 women. Each woman generally
attends AMS clinic once per month, so the investigators expect that it will take about three
months to capture all women at least once. These women will then be followed prospectively
over the next one-year time period to evaluate for uptake of a contraceptive method and
subsequent pregnancy. The investigators will then compare participants' method of
contraception used prior to the intervention and participants' method of contraception used
after the intervention. The investigators will specifically evaluate for an increase in the
use of IUCDs and contraceptive implants.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |